These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10220607)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
    Lewandowski CA; Kahler J
    Am Heart J; 1999 May; 137(5):S94-6. PubMed ID: 10220607
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Thrombolytic therapy: economic considerations.
    Krumholz HM
    Am Heart J; 1999 May; 137(5):S87-9. PubMed ID: 10220605
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 5. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of thrombolytic therapy for acute myocardial infarction.
    Castillo PA; Palmer CS; Halpern MT; Hatziandreu EJ; Gersh BJ
    Ann Pharmacother; 1997 May; 31(5):596-603. PubMed ID: 9161657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs and benefits of community thrombolysis for acute myocardial infarction : a decision-analytic model.
    Vale L; Steffens H; Donaldson C
    Pharmacoeconomics; 2004; 22(14):943-54. PubMed ID: 15362930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 12. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction.
    de Boer MJ; van Hout BA; Liem AL; Suryapranata H; Hoorntje JC; Zijlstra F
    Am J Cardiol; 1995 Oct; 76(11):830-3. PubMed ID: 7572666
    [No Abstract]   [Full Text] [Related]  

  • 13. Is intensive drug therapy appropriate for older patients?
    Gollub SB
    Lancet; 1999 Mar; 353(9157):940-1. PubMed ID: 10459896
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

  • 16. Critical concepts in cost-effectiveness for cardiovascular specialists.
    Califf RM; Eisenstein EL
    Am Heart J; 2000 Dec; 140(6 Suppl):S143-7. PubMed ID: 11100008
    [No Abstract]   [Full Text] [Related]  

  • 17. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of thrombolytic therapy following acute myocardial infarction.
    Fenn P; Gray AM; McGuire A
    Br J Clin Pract; 1991; 45(3):181-4. PubMed ID: 1805915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis--a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Timely thrombolysis in the acute myocardial infarction.
    Barthel W; Haustein KO
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):277-81. PubMed ID: 8832302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.